API | canertinib

canertinib Report issue

Small molecule Experimental

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Canertinib (CI-1033) is an experimental drug candidate for the treatment of cancer. It is an irreversible tyrosine-kinase inhibitor with activity against EGFR (IC50 0.8 nM), HER-2 (IC50 19 nM) and ErbB-4 (IC50 7 nM). By 2015, Pfizer had discontinued development of the drug. ^Wikipedia

Chemistry

SMILES: C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1
InChIKey: OMZCMEYTWSXEPZ-UHFFFAOYSA-N
Mol. Mass: 485.95
ALogP: 4.39 Partition coefficient
ChEMBL Molecules:

canertinib

canertinib dihydrochloride

More Chemistry

Pharmacology

Mechanisms of Action:
- Epidermal growth factor receptor (Homo sapiens) ^UniProt
- Receptor tyrosine-protein kinase erbB-2 (Homo sapiens) ^UniProt
- Receptor tyrosine-protein kinase erbB-4 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

canertinib | canertinib dihydrochloride | ci1033 | ci 1033 | ci-1033 | ci 980 | ci-980 | pd-0183805 | pd183805 | pd 183805 | pd-183805 | sn-26606

Organizations (1)

Research & Development (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (3)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (3)

Breast Neoplasms (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 1)

Lung Neoplasms (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 3
# of Trial Organizations: 1

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue